Evidence map›Paper›PMID 40386435›Full record

ArticleResearch square2025

Michael O Alberti, Sridhar Nonavinkere Srivatsan, Jin Shao, Dennis L Fei, Mengou Zhu, Clauida Cabrera Pastrana, Sarah Grieb, Timothy A Graubert, Omar Abdel-Wahab, Matthew J Walter

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Michael O AlbertiDepartment of Pathology and Immunology, Washington University, St. Louis, MO; Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO.
Sridhar Nonavinkere SrivatsanDepartment of Medicine, Washington University, St. Louis, MO.ORCID 0000-0001-6293-4632
Jin ShaoDepartment of Medicine, Washington University, St. Louis, MO.
Dennis L FeiDepartment of Medicine, Meyer Cancer Center, Weill Cornell Medicine, New York, NY; Cancer Biology Section, Cancer Genetics Branch, National Human Genome Research Institute, Bethesda, MD.
Mengou ZhuDepartment of Medicine, Washington University, St. Louis, MO.
Clauida Cabrera PastranaDepartment of Medicine, Washington University, St. Louis, MO.
Sarah GriebDepartment of Medicine, Washington University, St. Louis, MO.
Timothy A GraubertMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA.
Omar Abdel-WahabMemorial Sloan Kettering Cancer Center, New York, NY.
Matthew J WalterDepartment of Medicine, Washington University, St. Louis, MO.ORCID 0000-0002-7753-1091

Funding

Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI TIMOTHY J. EBERLEIN · 2001 to 2026
$128.0M
WU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8M
Specimen Acquistition and Expression ProfilingP01CA101937 · NCI · WASHINGTON UNIVERSITY · PI PAYTON, JACQUELINE E. · 2003 to 2023
$58.8M
Targeting the Bone Marrow Microenvironment In Acute Lymphocytic LeukemiaP50CA171963 · NCI · WASHINGTON UNIVERSITY · PI Daniel C Link · 2013 to 2026
$31.6M
The Memorial Sloan Kettering Cancer Center SPORE in LeukemiaP50CA254838 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Eytan Stein · 2021 to 2026
$16.8M
Washington University Paul Calabresi K12 Career Development Award for Clinical OncologyK12CA167540 · NCI · WASHINGTON UNIVERSITY · PI John F. Dipersio, Ramaswamy Govindan · 2012 to 2026
$11.7M
Genetic and molecular basis for SRSF2 mutations in myelodysplasiaR01HL128239 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Omar Abdel-Wahab, Robert K Bradley · 2015 to 2026
$8.0M
Interrogating the minor spliceosome to understand and treat leukemiaR01CA251138 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ABDEL-WAHAB, OMAR, BRADLEY, ROBERT K · 2020 to 2024
$3.3M
Synthetic introns for selective targeting of RNA splicing factor-mutant leukemiaR01CA283364 · NCI · FRED HUTCHINSON CANCER CENTER · PI Omar Abdel-Wahab, Robert K Bradley · 2023 to 2026
$2.9M
Targeting an RNA Binding Protein Network in Acute Myeloid LeukemiaR01CA242020 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ABDEL-WAHAB, OMAR, AIFANTIS, IANNIS · 2020 to 2024
$2.7M
Distinct roles of U2AF1 mutations in myelodysplastic syndrome pathogenesisK08HL159354 · NHLBI · WASHINGTON UNIVERSITY · PI ALBERTI, MICHAEL O · 2021 to 2025
$814k
Targeting Nonsense-Mediated RNA Decay in Splicing Factor Mutant Myeloid Malignancies.F31CA284751 · NCI · WASHINGTON UNIVERSITY · PI CABRERA, CLAUDIA · 2023 to 2024
$69k
NCATS NIH HHS UL1 TR002345NCI NIH HHS F31 CA284751NCI NIH HHS K12 CA167540NCI NIH HHS P01 CA101937NCI NIH HHS P30 CA091842NCI NIH HHS P50 CA171963NCI NIH HHS P50 CA254838NCI NIH HHS R01 CA242020NCI NIH HHS R01 CA251138NCI NIH HHS R01 CA283364NHLBI NIH HHS K08 HL159354NHLBI NIH HHS R01 HL128239
6 · The paper itself

Abstract

Recurrent somatic mutations in the spliceosome genes

Identifiers

PMID40386435
PMCPMC12083641

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.